Search Press releases

Press releases teaser image
10 Nov 2023

UCB receives CHMP positive opinion for rozanolixizumab for treatment of adults with generalized myasthenia gravis in Europe

Read More
Press releases teaser image
10 Nov 2023

UCB Presents New Five-Year Data on BIMZELX[®]▼(bimekizumab) in Ankylosing Spondylitis at ACR Convergence 2023

Read More
Press releases teaser image
9 Nov 2023

UCB successfully completes its offer to the public of fixed rate notes and decides to early terminate the subscription period

Read More
Press releases teaser image
7 Nov 2023

UCB launches an offer to the public of 6-year 5.20% fixed rate notes in Belgium and in Luxembourg

Read More
Press releases teaser image
1 Nov 2023

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session

Read More
Press releases teaser image
18 Oct 2023

BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe